New treatment strategies for multiple myeloma

被引：9

作者：

Hussein, MA ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Multiple Myeloma Res Ctr, Taussig Canc Ctr, Cleveland, OH 44195 USA

来源：

SEMINARS IN HEMATOLOGY | 2004年 / 41卷 / 04期

关键词：

D O I：

10.1053/j.seminhematol.2004.09.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multiple myeloma remains an incurable disease despite aggressive, high-dose therapy and intensive supportive care. Newer therapies with good safety profiles are needed for patients with multiple myeloma to improve the quality of responses and prolong survival. Novel treatment strategies for multiple myeloma include replacing conventional doxorubicin with pegylated liposomal doxorubicin and reducing the dexamethasone dose (DVd) in the widely accepted VAD (vincristine, conventional doxorubicin, dexamethasone) regimen to improve the safety profile. Because of its antiangiogenic and immunomodulatory effects, thalidomide has also been explored for use in the treatment of multiple myeloma and has demonstrated increased response rates when used in combination with dexamethasone. These findings subsequently led to the evaluation of the role of thalidomide in combination with pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone (the DVd-T regimen). This regimen was associated with response rates greater than 80% in patients with both newly diagnosed and relapsed/refractory multiple myeloma. Future applications of this and similar regimens for the treatment of multiple myeloma are currently being explored. © 2004 Elsevier Inc. All rights reserved.

引用

页码：2 / 8

页数：7

共 39 条

[1]

AGRAWAL NR, 2003, 45 ANN M AM SOC HEM

[2] VAD-BASED REGIMENS AS PRIMARY-TREATMENT FOR MULTIPLE-MYELOMA [J].

ALEXANIAN, R ;

BARLOGIE, B ;

TUCKER, S .

AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (02) :86-89

[3] EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS [J].

BARLOGIE, B ;

SMITH, L ;

ALEXANIAN, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1353-1356

[4] The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin [J].

Berry, G ;

Billingham, M ;

Alderman, E ;

Richardson, P ;

Torti, F ;

Lum, B ;

Patek, A ;

Martin, FJ .

ANNALS OF ONCOLOGY, 1998, 9 (07) :711-716

[5] Transplantation for multiple myeloma:: who, when, how often?: High-dose therapy in multiple myeloma [J].

Bladé, J .

BLOOD, 2003, 102 (10) :3469-3470

[6] MODIFIED ADRIAMYCIN VINCRISTINE DEXAMETHASONE (M-VAD) IN PRIMARY REFRACTORY AND RELAPSED PLASMA-CELL MYELOMA - AN NCI (CANADA) PILOT-STUDY [J].

BROWMAN, GP ;

BELCH, A ;

SKILLINGS, J ;

WILSON, K ;

BERGSAGEL, D ;

JOHNSTON, D ;

PATER, JL .

BRITISH JOURNAL OF HAEMATOLOGY, 1992, 82 (03) :555-559

[7] Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B [J].

Chauhan, D ;

Uchiyama, H ;

Akbarali, Y ;

Urashima, M ;

Yamamoto, K ;

Libermann, TA ;

Anderson, KC .

BLOOD, 1996, 87 (03) :1104-1112

[8] Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines [J].

Damiano, JS ;

Cress, AE ;

Hazlehurst, LA ;

Shtil, AA ;

Dalton, WS .

BLOOD, 1999, 93 (05) :1658-1667

[9] Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma [J].

Dimopoulos, MA ;

Pouli, A ;

Zervas, K ;

Grigoraki, V ;

Symeonidis, A ;

Repoussis, P ;

Mitsouli, C ;

Papanastasiou, C ;

Margaritis, D ;

Tokmaktsis, A ;

Katodritou, I ;

Kokkini, G ;

Terpos, E ;

Vyniou, N ;

Tzilianos, M ;

Chatzivassili, A ;

Kyrtsonis, MC ;

Panayiotidis, P ;

Maniatis, A .

ANNALS OF ONCOLOGY, 2003, 14 (07) :1039-1044

[10]

FARRAY D, 2002, P AN M AM SOC CLIN, V21, pA276

← 1 2 3 4 →